Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance (WBA) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $1 per share a year ago.

Walgreens Boots Alliance (WBA) Q3 Earnings Miss Estimates

Adjusted earnings at the drugstore chain miss analysts' estimates.

Walgreens Stock Falls. A Pressured Consumer Leads to Earnings Guidance Cut.

Walgreen Boots Alliance cut its profit forecast for fiscal 2024 and announced store closures on Thursday, citing challenging pharmacy industry trends and a worse-than-expected U.S. consumer environment.

Walgreens cuts 2024 profit forecast, announces store closures

Walgreens Boots Alliance Inc (NASDAQ: WBA) trading down this morning after reporting weaker-than-expected financial results for its third quarter.  Shares of the healthcare giant are now down close to 50% for the year.

Walgreen misses Q3 expectations and disappoints on guidance

Walgreens reported fiscal third-quarter earnings that fell short of expectations and slashed its full-year adjusted profit outlook due to a "challenging" environment for pharmacies and U.S. consumers.  The company topped revenue estimates for the quarter on strong performance in its health-care segment.

Walgreens slashes profit guidance, citing 'challenging' environment for consumers and pharmacies

Walgreens Boots Alliance Thursday reported $344 million in its third quarter as chief executive Tim Wentworth asked for patience as the drugstore giant executes its plan for a financial turnaround.

Walgreens Turns $344 Million Profit As CEO Asks Patience On Turnaround

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2024, which ended May 31, 2024. Chief Executive Officer Tim Wentworth said: "We continue to face a difficult operating environment, including persistent pressures on the U.S. consumer and the impact of recent marketplace dynamics which have eroded pharmacy margins. Our results and outlook reflect these headwinds, despite solid performance in both our I.

Walgreens Boots Alliance Reports Fiscal 2024 Third Quarter Results

Walgreens Boots Alliance Chief Executive Tim Wentworth is taking the struggling chain in a new direction, planning to close a substantial number of poorly performing stores and pulling back on the company's ambitious plunge into the primary-care business.

Walgreens Plans Major U.S. Store Closures

Walgreens (NASDAQ: WBA) is scheduled to report its fiscal Q3 2024 results on Thursday, June 27 (Walgreens' fiscal ends in August). We expect WBA stock to trade higher post the Q3 announcement, with its revenue and earnings expected to be above the street estimates.

Walgreens Likely To Post A 25% Drop In Q3 Earnings

General Mills

Micron Technology

CNBC's Jim Cramer guided investors through this week's most important Wall Street action, highlighting earnings reports from Micron, Walgreens and General Mills. He also noted that Monday was tough for Big Tech, but expressed continued faith in the success of the megacaps in that sector.

Cramer's week ahead: Earnings from Micron, Walgreens and General Mills

Get a deeper insight into the potential performance of Walgreens (WBA) for the quarter ended May 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Exploring Analyst Estimates for Walgreens (WBA) Q3 Earnings, Beyond Revenue and EPS

Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Walgreens Boots Alliance (WBA) Q3 Earnings Expected to Decline

DEERFIELD, Ill.--(BUSINESS WIRE)--To express gratitude for an incredibly significant part of American history and to honor those who have served – and continue to serve – our country, Walgreens is offering an Independence Day weekend discount to all veterans, active-duty military personnel and their immediate family members. Beginning July 4 through July 7, customers with a valid military ID or proof of service will receive 20 percent off eligible regular-price products with MyWalgreens, at any.

Walgreens Honors Veterans, Active-Duty Military on Independence Day

CVS Health

Warner Bros Discovery Inc

Investors must be cautious about the kinds of stocks with the most growth potential and good fundamentals to maximize returns while minimizing risks. Key fundamentals should lie at the helm of the strategy.

3 Must-Buy Stocks for Long-Term Gains: June 2024

B&G Foods

Cato

NextEra Energy

Wendy's

Whirlpool

Xerox

There are many dividend stocks that make for great long-term investments, but conversely, there are many dividend stocks to sell before they wreak havoc on your portfolio. The prospect of steady, cash-based returns is one of the main areas of appeal with dividend stocks, particularly high-yield dividend stocks.

7 Dividend Stocks to Sell in June Before They Crash & Burn

AGNC Investment

Ardagh Metal Packaging SA

Brandywine Realty

Kohl's

Service Properties Trust

Navigating the world of high yield dividend stocks can be difficult. While those high yields reduce overall investor risk when share prices go down, they also require significant capital for their continued payment.

7 At Risk Dividend Stocks Investors Should Sell Before It's Too Late

Starbucks

Dividend stocks have lapped non-payers in the return column over the last 50 years. A top-tier consumer-facing business with a nearly 3% yield, strong brand loyalty, and a lengthy track record of innovation, can make its patient investors richer.

Time to Pounce: 2 Beaten-Down, High-Yield Nasdaq-100 Stocks That Are Begging to Be Bought Right Now

Super Micro Computer

On Thursday evening, the index added Arm Holdings, the U.K. chip maker, and dropped Sirius XM Holdings in a move that Barron's had predicted could happen.

Super Micro Could Be Next to Join Nasdaq 100. Walgreens Could Be Dropped.

Analysts have been downgrading Walgreens shares, but they still see a lot of potential upside. The stock trades at a low earnings multiple and it's right around its book value.

How Low Can Walgreens Boots Alliance Stock Go?

Chevron

Dow Inc

Verizon

24/7 Insights The Dow Jones industrials are up over 10% this year.

5 Dogs of the Dow Offer Huge Passive Income Potential in June

DEERFIELD, Ill. & SAN FRANCISCO--(BUSINESS WIRE)--Walgreens and Greater Than HIV, a public information initiative of KFF, are teaming up with health departments and community organizations to offer free rapid HIV testing in more than 550 Walgreens stores on June 27 in the largest coordinated National HIV Testing Day event. Additionally, to address the rising rates of other sexually transmitted diseases (STDs), free rapid syphilis and/or hepatitis C testing will also be offered by partners this.

Walgreens and KFF's Greater Than HIV Join with Community Partners to Offer Free HIV and STD Testing at Record Number of Stores on June 27

London's stock market suffered another blow when the Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A) revealed it had axed plans to list the British high street pharmacy chain. Hopes for a UK float have been swapped with plots for a sale, with private equity firms believed to be interested in the group, Bloomberg revealed.

Boots snubs London listing; looks for take-private sale instead

Walgreens Boots Alliance Inc. is understood to have ditched plans for a potential initial public offering (IPO) of its U.K. drugstore giant Boots.

Walgreens Looks For Boots Buyers Again As IPO Plans Put On Ice

Walgreens-backed CityMD will pay $12.04 million to settle Covid fraud allegations brought by the Department of Justice. For two years of the pandemic, CityMD allegedly obtained fraudulent government reimbursements for Covid tests by submitting false claims to a Covid program specifically designated for uninsured patients, even when their patients had health insurance.

DOJ settles CityMD Covid fraud allegations for $12 million

Altria

Walgreens Boots Alliance cut its dividend earlier this year, but even with the new payout, its yield remains high. Altria faces a challenging road ahead as tobacco use declines, but the company's dividend still looks safe right now.

News for Walgreens Stock (WBA)